Female Sexual Dysfunction in Patients Treated with Antidepressant-Comparison between Escitalopram and Fluoxetine

Hatta Sidi, Duni Asmidar, Rozita Hod, Ng Chong Guan

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

Introduction. Selective serotonin reuptake inhibitor is one of the most widely used antidepressant and commonly associated with female sexual dysfunction (FSD). Aims. This study compares the prevalence of FSD between patients on escitalopram and fluoxetine. The risk factors for FSD were also examined. Methods. A cross-sectional study involved 112 female depressed patients (56 each group) who were in remission (as defined in the fourth edition of Diagnostic and Statistical Manual of Mental Disorders [DSM-IV] during the past 2 months with no significant signs or symptoms of the disturbance and Montgomery-Asberg Depression Rating Scale score of ≤10) from the psychiatric clinic in a university hospital. The rates of sexual dysfunction between the two groups were compared. Main Outcome Measures. The subjects were interviewed by using Structured Clinical Interview for DSM-IV. Sexual dysfunction was assessed with the Malay Version of the Female Sexual Function Index. Results. The prevalence of FSD was 44.6% for all patients, 55.4% for the fluoxetine group, and 33.9% for the escitalopram group. Multivariate logistic regression analysis showed no significant difference in the risk of FSD between the two groups. Moderate to high dosing was the only significant associated factor for FSD (odds ratio=4.89, 95% confidence interval=1.94-12.33). Conclusion. There was no significant difference in the risk of having FSD between patients treated with fluoxetine or escitalopram. Patients on higher dosage of antidepressant have higher risk of having FSD. Sidi H, Asmidar D, Hod R, and Ng CG. Female sexual dysfunction in patients treated with antidepressant-comparison between escitalopram and fluoxetine.

Original languageEnglish
Pages (from-to)1392-1399
Number of pages8
JournalJournal of Sexual Medicine
Volume9
Issue number5
DOIs
Publication statusPublished - May 2012

Fingerprint

Citalopram
Fluoxetine
Antidepressive Agents
Diagnostic and Statistical Manual of Mental Disorders
Cross-Sectional Studies
Serotonin Uptake Inhibitors
Signs and Symptoms
Psychiatry
Logistic Models
Odds Ratio
Regression Analysis
Outcome Assessment (Health Care)
Confidence Intervals
Interviews

Keywords

  • Antidepressant
  • Escitalopram
  • Female sexual dysfunction
  • Fluoxetine
  • Major depressive disorder
  • Selective serotonin reuptake inhibitor

ASJC Scopus subject areas

  • Urology
  • Obstetrics and Gynaecology
  • Reproductive Medicine

Cite this

Female Sexual Dysfunction in Patients Treated with Antidepressant-Comparison between Escitalopram and Fluoxetine. / Sidi, Hatta; Asmidar, Duni; Hod, Rozita; Guan, Ng Chong.

In: Journal of Sexual Medicine, Vol. 9, No. 5, 05.2012, p. 1392-1399.

Research output: Contribution to journalArticle

@article{1634bb01cf0145b0a7887c1f8cd750a6,
title = "Female Sexual Dysfunction in Patients Treated with Antidepressant-Comparison between Escitalopram and Fluoxetine",
abstract = "Introduction. Selective serotonin reuptake inhibitor is one of the most widely used antidepressant and commonly associated with female sexual dysfunction (FSD). Aims. This study compares the prevalence of FSD between patients on escitalopram and fluoxetine. The risk factors for FSD were also examined. Methods. A cross-sectional study involved 112 female depressed patients (56 each group) who were in remission (as defined in the fourth edition of Diagnostic and Statistical Manual of Mental Disorders [DSM-IV] during the past 2 months with no significant signs or symptoms of the disturbance and Montgomery-Asberg Depression Rating Scale score of ≤10) from the psychiatric clinic in a university hospital. The rates of sexual dysfunction between the two groups were compared. Main Outcome Measures. The subjects were interviewed by using Structured Clinical Interview for DSM-IV. Sexual dysfunction was assessed with the Malay Version of the Female Sexual Function Index. Results. The prevalence of FSD was 44.6{\%} for all patients, 55.4{\%} for the fluoxetine group, and 33.9{\%} for the escitalopram group. Multivariate logistic regression analysis showed no significant difference in the risk of FSD between the two groups. Moderate to high dosing was the only significant associated factor for FSD (odds ratio=4.89, 95{\%} confidence interval=1.94-12.33). Conclusion. There was no significant difference in the risk of having FSD between patients treated with fluoxetine or escitalopram. Patients on higher dosage of antidepressant have higher risk of having FSD. Sidi H, Asmidar D, Hod R, and Ng CG. Female sexual dysfunction in patients treated with antidepressant-comparison between escitalopram and fluoxetine.",
keywords = "Antidepressant, Escitalopram, Female sexual dysfunction, Fluoxetine, Major depressive disorder, Selective serotonin reuptake inhibitor",
author = "Hatta Sidi and Duni Asmidar and Rozita Hod and Guan, {Ng Chong}",
year = "2012",
month = "5",
doi = "10.1111/j.1743-6109.2011.02256.x",
language = "English",
volume = "9",
pages = "1392--1399",
journal = "Journal of Sexual Medicine",
issn = "1743-6095",
publisher = "Wiley-Blackwell",
number = "5",

}

TY - JOUR

T1 - Female Sexual Dysfunction in Patients Treated with Antidepressant-Comparison between Escitalopram and Fluoxetine

AU - Sidi, Hatta

AU - Asmidar, Duni

AU - Hod, Rozita

AU - Guan, Ng Chong

PY - 2012/5

Y1 - 2012/5

N2 - Introduction. Selective serotonin reuptake inhibitor is one of the most widely used antidepressant and commonly associated with female sexual dysfunction (FSD). Aims. This study compares the prevalence of FSD between patients on escitalopram and fluoxetine. The risk factors for FSD were also examined. Methods. A cross-sectional study involved 112 female depressed patients (56 each group) who were in remission (as defined in the fourth edition of Diagnostic and Statistical Manual of Mental Disorders [DSM-IV] during the past 2 months with no significant signs or symptoms of the disturbance and Montgomery-Asberg Depression Rating Scale score of ≤10) from the psychiatric clinic in a university hospital. The rates of sexual dysfunction between the two groups were compared. Main Outcome Measures. The subjects were interviewed by using Structured Clinical Interview for DSM-IV. Sexual dysfunction was assessed with the Malay Version of the Female Sexual Function Index. Results. The prevalence of FSD was 44.6% for all patients, 55.4% for the fluoxetine group, and 33.9% for the escitalopram group. Multivariate logistic regression analysis showed no significant difference in the risk of FSD between the two groups. Moderate to high dosing was the only significant associated factor for FSD (odds ratio=4.89, 95% confidence interval=1.94-12.33). Conclusion. There was no significant difference in the risk of having FSD between patients treated with fluoxetine or escitalopram. Patients on higher dosage of antidepressant have higher risk of having FSD. Sidi H, Asmidar D, Hod R, and Ng CG. Female sexual dysfunction in patients treated with antidepressant-comparison between escitalopram and fluoxetine.

AB - Introduction. Selective serotonin reuptake inhibitor is one of the most widely used antidepressant and commonly associated with female sexual dysfunction (FSD). Aims. This study compares the prevalence of FSD between patients on escitalopram and fluoxetine. The risk factors for FSD were also examined. Methods. A cross-sectional study involved 112 female depressed patients (56 each group) who were in remission (as defined in the fourth edition of Diagnostic and Statistical Manual of Mental Disorders [DSM-IV] during the past 2 months with no significant signs or symptoms of the disturbance and Montgomery-Asberg Depression Rating Scale score of ≤10) from the psychiatric clinic in a university hospital. The rates of sexual dysfunction between the two groups were compared. Main Outcome Measures. The subjects were interviewed by using Structured Clinical Interview for DSM-IV. Sexual dysfunction was assessed with the Malay Version of the Female Sexual Function Index. Results. The prevalence of FSD was 44.6% for all patients, 55.4% for the fluoxetine group, and 33.9% for the escitalopram group. Multivariate logistic regression analysis showed no significant difference in the risk of FSD between the two groups. Moderate to high dosing was the only significant associated factor for FSD (odds ratio=4.89, 95% confidence interval=1.94-12.33). Conclusion. There was no significant difference in the risk of having FSD between patients treated with fluoxetine or escitalopram. Patients on higher dosage of antidepressant have higher risk of having FSD. Sidi H, Asmidar D, Hod R, and Ng CG. Female sexual dysfunction in patients treated with antidepressant-comparison between escitalopram and fluoxetine.

KW - Antidepressant

KW - Escitalopram

KW - Female sexual dysfunction

KW - Fluoxetine

KW - Major depressive disorder

KW - Selective serotonin reuptake inhibitor

UR - http://www.scopus.com/inward/record.url?scp=84856552201&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84856552201&partnerID=8YFLogxK

U2 - 10.1111/j.1743-6109.2011.02256.x

DO - 10.1111/j.1743-6109.2011.02256.x

M3 - Article

VL - 9

SP - 1392

EP - 1399

JO - Journal of Sexual Medicine

JF - Journal of Sexual Medicine

SN - 1743-6095

IS - 5

ER -